Bahrain announces extension of Covishield-AstraZeneca dosing intervals

Bahrain announces extension of Covishield-AstraZeneca dosing intervals
The vaccine is manufactured by the Serum Institute of India under the name ‘Covishield’. (File/AFP)
Short Url
Updated 27 February 2021

Bahrain announces extension of Covishield-AstraZeneca dosing intervals

Bahrain announces extension of Covishield-AstraZeneca dosing intervals
  • The vaccine was approved for emergency use for vulnerable groups in the Kingdom starting Jan. 21
  • The vaccine was produced by AstraZeneca in cooperation with the University of Oxford

DUBAI: Bahrain has announced it is increasing the number of weeks between the first and second dose of the Covishield-AstraZeneca vaccine from four to eight weeks, state news agency BNA reported.
The World Health Organization (WHO) said the longer dose durations between eight to 12 weeks are related to greater vaccine effectiveness, the Ministry of Health’s Undersecretary for Public Health Dr. Mariam Al-Hajeri said.
The vaccine was approved for emergency use for vulnerable groups in the Kingdom starting Jan. 21. The groups include the elderly and those with immune complications, she said.
The vaccine was produced by AstraZeneca in cooperation with the University of Oxford and is manufactured by the Serum Institute of India under the name ‘Covishield’.